Relypsa Inc (RLYP)

[H2R]

Moussatos: PT $52, Sanofi likely buyer

See http://www.smarteranalyst.com/2016/04/08/relypsa-inc-rlyp-intercept-pharmaceuticals-inc-icpt-attract-analysts-light-potential-acquisition-favorable-fdas-panel-outcome/

Wedbush analyst Liana Moussatos was the first to comment: “We previously looked at the phosphate binder market and based on Symphony Health estimates for total prescriptions, we calculated Renagel and Renvaler (both have the sevelamer polymer as the active ingredient) together have over 80% of the total phosphate binder annual prescriptions and that Sanofi has been clearly successful in our view at counter detailing metal-based phosphate binders. Sanofi and Relypsa have a two year co-detailing contract for Veltassa and we believe Sanofi’s involvement – especially with their salespeople’s presumed long-term relationships with nephrologists who prescribe phosphate binders – is likely to accelerate Veltassa uptake. Because Veltassa is a non-metal polymer like Sanofi’s phosphate binders, we see it as a great addition for their salespeople. Consequently, we would not be surprised if Sanofi is the eventual acquirer.”

Moussatos reiterated an Outperform rating on shares of Relypsa, with a price target of $52, which represents a potential upside of 114% from where the stock is currently trading.

According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Liana Moussatos has a yearly average return of 10% and a 39% success rate. Moussatos has a 4% average return when recommending RLYP, and is ranked #234 out of 3780 analysts.